Last updated 2026-07-26
TL;DR
CJC-1295's human evidence is thin: essentially one 2005 clinical pharmacology study (Teichman et al., n=falls between low dozens across dose cohorts) showing sustained GH and IGF-1 increases. The rest of the mechanistic case leans on decades of older GHRH animal and cell-culture research. No published trials test CJC-1295 for muscle gain, fat loss, or long-term safety in healthy adults.
What is CJC-1295, exactly, and why does the animal-vs-human distinction matter here?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), engineered to resist the enzyme (DPP-4) that normally chops native GHRH apart within minutes [1]. The modification extends its half-life dramatically compared to endogenous GHRH, which is why it got attention as a long-acting GH secretagogue in the first place. The distinction matters because most of what people repeat about CJC-1295 online, dosing schedules, stacking logic, claimed fat-loss or recovery effects, comes from bodybuilding forums, not peer-reviewed research. The actual published science is narrow: rodent and cell-based GHRH pharmacology going back to the 1980s, and one human pharmacokinetic/pharmacodynamic study from 2005 that is still, two decades later, the primary citation almost every downstream article and product page points to [2]. That's not a knock on the compound's mechanism, which is grounded in real, well-characterized GHRH receptor biology. It's a statement about the evidence base for CJC-1295 specifically, as opposed to GHRH physiology in general. Those are not the same thing, and conflating them is where a lot of confident-sounding online claims fall apart. For a plain mechanism overview before you get into the study weeds, see cjc 1295.
What does the animal research on GHRH and CJC-1295 actually show?
The animal literature here is mostly about GHRH itself, not the modified CJC-1295 molecule. Foundational work in rats and other species through the 1980s and 1990s established that GHRH, given by injection or infusion, triggers pulsatile GH release from the anterior pituitary, and that this pathway is central to normal somatic growth regulation [3]. That work underpins the entire GH secretagogue field, including later drugs like tesamorelin and sermorelin. The animal data specific to DAC-modified, long-acting GHRH analogues (the class CJC-1295 belongs to) is thinner and mostly preclinical/pharmacology-stage, feeding into the patent and development work by ConjuChem, the company that originally developed the Drug Affinity Complex (DAC) technology used to extend the molecule's half-life [4]. Public, peer-reviewed animal efficacy or toxicology papers specifically on CJC-1295 (as opposed to GHRH generally) are not widely available in open literature; most of what exists lives in patents and industry pharmacology summaries rather than journals with full methods sections. So when someone says 'animal studies prove CJC-1295 works,' the honest answer is: animal studies prove GHRH signaling works, and that the DAC modification extends a molecule's circulating half-life in principle. That is a real and useful finding. It is not the same as demonstrating that CJC-1295 itself produces a specific outcome (muscle gain, injury healing, longevity) in a living animal over weeks or months, because that longer-term efficacy data isn't published in a form outside reviewers can check.
What is the human evidence for CJC-1295, and how strong is it really?
The core human dataset is a 2005 study by Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism, titled 'Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Growth-Hormone-Releasing Hormone Analog' [2]. This is the single most-cited human source in the entire CJC-1295 conversation, and it's worth being precise about what it did and didn't do. The study tested single and multiple doses of CJC-1295 (called by its earlier designation, DAC:GRF, in the paper) in healthy adults, measuring GH and IGF-1 response over time. The reported result: a single injection raised mean plasma GH levels for six or more days, and repeated dosing (every 7 to 14 days over multiple weeks) produced sustained increases in IGF-1, in some cohorts more than doubling baseline IGF-1 concentrations [2]. The study's own conclusion states that CJC-1295 'was safe and well tolerated' at the doses tested and produced 'sustained, dose-dependent increases' in GH and IGF-1. That is a real, legitimate clinical pharmacology finding. But it is one study, industry-sponsored (ConjuChem), short in duration, and focused on pharmacokinetics and pharmacodynamics (does the drug raise GH/IGF-1, and for how long) rather than clinical outcomes like body composition, strength, wound healing, or bone density. It also predates any long-term safety follow-up. No published randomized controlled trial has since tested CJC-1295 for a specific therapeutic or performance endpoint in humans over months or years. Compare that to tesamorelin, a related GHRH analogue, which has actual FDA-reviewed Phase 3 trial data supporting its approval for HIV-associated lipodystrophy, including defined reductions in visceral adipose tissue measured by CT scan [5]. CJC-1295 has nothing comparable. It has never gone through an FDA new drug application review, and no FDA-approved product contains it [6].
CJC-1295 with DAC vs without DAC: what's the actual evidence difference?
This distinction gets blurred constantly in casual writing, so it's worth being exact. CJC-1295 with DAC is the molecule from the 2005 Teichman study, the version modified with Drug Affinity Complex technology so it binds serum albumin and circulates far longer, producing that multi-day GH elevation [2]. CJC-1295 without DAC is a different, shorter-acting peptide, functionally closer to a modified GRF(1-29) fragment, sometimes marketed as 'Mod GRF 1-29.' It's cleared from the body in roughly 30 minutes, similar to native GHRH's short half-life, rather than the days-long profile of the DAC version [1]. Here's the evidence gap most people miss: the human pharmacology data (the 2005 study) is specifically for the DAC version. The no-DAC version's popularity in the secretagogue community is built almost entirely on the theoretical argument that a shorter-acting GHRH analogue produces a GH pulse closer to the body's natural rhythm, avoiding the sustained, non-pulsatile IGF-1 elevation critics worry about with the DAC form. That's a reasonable mechanistic hypothesis. It is not something that's been tested head-to-head in a published human trial comparing the two versions on any outcome. So if someone tells you 'no-DAC is proven better for pulsatile release,' push back gently: proven where? The pulsatility logic is grounded in real GH physiology (GH is normally secreted in bursts, not steady-state), but no controlled study has compared DAC vs no-DAC CJC-1295 outcomes in humans. It's a plausible theory riding on borrowed physiology, not a demonstrated result. For the full mechanism and half-life comparison between the two forms, see cjc 1295 with dac.
Why is CJC-1295 almost always paired with ipamorelin, and does that combination have separate evidence?
The rationale is mechanistic and reasonably sound as pharmacology, even though the combination itself hasn't been through a dedicated published clinical trial. CJC-1295 works on GHRH receptors in the pituitary. Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue of a different class, sometimes called a GHRP), working through a separate receptor pathway [7]. Stimulating both pathways at once is a well-established strategy in endocrine pharmacology generally, since GHRH and ghrelin-receptor agonists combine to produce a larger GH pulse than either alone in earlier human research using other combinations (for example, GHRP-6 or GHRP-2 paired with GHRH itself) [7]. That combined-effect research, though, is largely from studies using older secretagogue combinations, not CJC-1295 and ipamorelin specifically as a branded pairing. Ipamorelin itself has separate published human data (small trials in the 1990s-2000s looking at GH release and gastric motility applications, since discontinued from full clinical development) [8], but no trial has tested the CJC-1295 (with or without DAC) plus ipamorelin combination as a unit for any defined outcome in humans. So the honest framing is: the biological logic for pairing a GHRH analogue with a ghrelin-receptor agonist is real and supported by older combination studies using different specific drugs. The specific product pairing popular today has not itself been through that testing. Anyone claiming a settled, published clinical outcome for 'CJC-1295 plus ipamorelin' as a stack is going beyond what the literature actually supports.
How does CJC-1295's evidence base compare to other GH secretagogues like sermorelin or tesamorelin?
| Tesamorelin | FDA-approved (Egrifta) for HIV lipodystrophy [5] | Multiple Phase 3 RCTs, published safety follow-up | FDA label, NEJM/clinical endocrinology journals | |
|---|---|---|---|---|
| Sermorelin | Formerly FDA-approved (Geref, now discontinued commercially) [9] | Multiple human trials from 1980s-1990s | FDA historical approval record | |
| CJC-1295 (with DAC) | Never FDA-approved; not a legal drug product for human use [6] | One published PK/PD study (2005) [2] | Teichman et al., JCEM | |
| CJC-1295 (no-DAC) | Never FDA-approved | No dedicated published human trial identified | Extrapolated from GHRH physiology | |
| Ipamorelin | Never FDA-approved for a marketed indication | Small early trials, discontinued development | Early 2000s pharmacology literature [8] | The pattern is clear: compounds with FDA approval have gone through the multi-phase trial process with defined endpoints, dose-ranging, and post-market safety tracking. CJC-1295 has one human PK/PD study and decades-old GHRH animal physiology behind it. That's a real evidence base, just a much thinner one than people assume when a compound is this widely discussed online. |
This is where the gap becomes concrete. Below is a rough comparison of the regulatory and evidence status for the main GHRH-class compounds people compare to CJC-1295. | Compound | FDA status | Human trial depth | Primary evidence source |
Is CJC-1295 legal, and is it approved for any use in humans?
No. CJC-1295 has never received FDA approval for any indication, and it is not a component of any approved drug product [6]. It exists in a research-chemical and compounding gray zone: sold by some research suppliers labeled 'not for human consumption,' and used off-label by clinics and individuals despite that labeling. The FDA has flagged compounded GH secretagogues more broadly in past guidance on bulk drug substances not eligible for compounding, noting concerns about a lack of adequate safety and efficacy data for many peptides in this category [6]. If you're evaluating a source, the labeling and paperwork matter: a provider that discloses sourcing, batch testing, and works with a licensed pharmacy is a meaningfully different risk profile than an anonymous vial with no documentation. See cjc 1295 for sale for what to actually check before buying.
What are the known and theoretical side effects, based on actual data vs speculation?
The 2005 Teichman study reported the treatment as 'safe and well tolerated' at studied doses over the trial's short duration, with adverse events consistent with known GH-axis effects (injection site reactions, and expected physiologic responses to elevated GH/IGF-1) [2]. That's the extent of controlled human safety data. What's not established: long-term safety over months or years of use, effects in people with pre-existing conditions (diabetes, cancer history, cardiovascular disease), interaction risk with other medications, or safety in populations outside the healthy-adult study cohort. Elevated IGF-1 over sustained periods is a biologically plausible concern worth taking seriously, since IGF-1 signaling intersects with cell growth pathways, but no long-term human cohort study on CJC-1295 exists to quantify that risk directly. This is inference from general GH-axis biology, not a CJC-1295-specific finding. For the fuller rundown of reported and theoretical side effects, see cjc 1295 side effects.
What dosing did the actual human study use, and how does that compare to what's used in practice?
The Teichman 2005 study tested a range of single and multiple-dose regimens in its cohorts, with repeated dosing schedules spaced roughly one to two weeks apart, given the drug's extended half-life from the DAC modification [2]. Doses in that trial were measured in micrograms per kilogram of body weight, administered as subcutaneous or intravenous injections under clinical supervision with lab monitoring of GH and IGF-1. That is quite different from typical community protocols, which usually recommend the no-DAC version dosed daily or near-daily (since it clears in about 30 minutes and doesn't need weekly spacing), often paired with ipamorelin, at doses derived from forum consensus rather than published dose-finding trials. Because no-DAC CJC-1295 has essentially no dedicated human trial data of its own, those daily protocols rest on extrapolation from GHRH pharmacology and from the DAC study's dose-response curves, not from a study of the actual product being used. If you want the practical breakdown of how doses are typically calculated and why the DAC and no-DAC schedules differ so much, see cjc 1295 dosage and the cjc-1295 dac dosage calculator.
What claims about CJC-1295 are folklore, not evidence?
A short, honest list, because this is where most of the internet gets sloppy. Claims with real data behind them: CJC-1295 (DAC form) raises GH and IGF-1 for multiple days after a single dose, and repeated dosing sustains elevated IGF-1 over weeks, per the one published human trial [2]. GHRH signaling itself is well-characterized physiology going back decades of animal and human research [3]. Claims without published human data: that CJC-1295 builds meaningful muscle mass on its own, that it produces measurable fat loss as a standalone intervention, that it improves sleep quality beyond what elevated GH generally does, that it speeds injury or tendon healing, that no-DAC is definitively 'better' than DAC for any outcome, or that stacking with ipamorelin produces effects greater than either drug's known individual mechanism would predict. These are plausible extrapolations from GH-axis biology in some cases, and pure forum lore in others. Neither category has been tested in a controlled CJC-1295 human trial with those specific endpoints.
Where can you actually find the primary sources yourself?
If you want to check the claims in this article rather than trust a summary of it, the two documents worth reading directly are the Teichman et al. 2005 paper in the Journal of Clinical Endocrinology & Metabolism [2], which is the actual human pharmacology trial, and the FDA's Egrifta (tesamorelin) approval materials [5], useful as a contrast for what a fully trial-supported GHRH analogue's evidence package looks like next to CJC-1295's. If you're weighing a purchase decision rather than a research question, look for a provider that is upfront about third-party lab testing and works through a named, licensed pharmacy partner rather than an unmarked vial supplier. CJC-1295 Co reviews providers on exactly that basis, and does not compound or manufacture anything itself; it points readers toward provider-reviewed sourcing routes and names the fulfilling pharmacy partner where one is used, so you can verify the chain yourself rather than taking a label's word for it.
Frequently asked questions
Is there any published human clinical trial on CJC-1295?
Yes, one primary trial: Teichman et al., 2005, in the Journal of Clinical Endocrinology & Metabolism, testing CJC-1295 (DAC form) in healthy adults for GH and IGF-1 response. It found sustained increases in both markers and reported the drug as safe and well tolerated at studied doses over the trial's short duration. No other major published human trial exists for this specific compound.
Do animal studies prove CJC-1295 works in humans?
Animal studies establish that GHRH signaling triggers GH release, which is a real and well-documented physiological pathway. But CJC-1295-specific animal efficacy data isn't widely published in open journals; most of that development-stage work sits in patents rather than peer-reviewed papers. Animal GHRH biology supports the mechanism; it doesn't substitute for CJC-1295-specific human outcome data.
What's the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds serum albumin, extending its half-life to multiple days, and is the version tested in the 2005 human study. CJC-1295 without DAC (Mod GRF 1-29) clears in about 30 minutes, similar to native GHRH. The DAC version has published human PK/PD data; the no-DAC version's dosing logic is extrapolated, not separately trial-tested.
Why do people combine CJC-1295 with ipamorelin?
CJC-1295 stimulates GHRH receptors while ipamorelin stimulates ghrelin receptors, a separate GH-release pathway. Combining GHRH and ghrelin-receptor agonists has shown a larger combined GH pulse effect in older studies using different specific drugs. No trial has tested the CJC-1295-plus-ipamorelin combination itself for a defined clinical outcome.
Is CJC-1295 FDA-approved?
No. CJC-1295 has never been approved by the FDA for any indication and isn't an ingredient in any approved drug product. It's typically sold as a research chemical, which means it lacks the safety and efficacy review process that approved GH-axis drugs like tesamorelin have gone through.
How does CJC-1295's evidence compare to tesamorelin's?
Tesamorelin has multiple published Phase 3 randomized controlled trials and FDA approval for HIV-associated lipodystrophy, with defined endpoints like CT-measured visceral fat reduction. CJC-1295 has one human pharmacokinetics/pharmacodynamics study and no FDA approval. The evidence depth is not comparable.
What side effects does the human study report for CJC-1295?
The 2005 Teichman study reported CJC-1295 as safe and well tolerated at the doses tested, with adverse events consistent with expected GH-axis physiology and injection site reactions. Long-term safety over months or years hasn't been studied in a published human cohort, so risks beyond the short trial period are inferred, not directly measured.
Does CJC-1295 build muscle or burn fat, based on real data?
No published human trial has tested CJC-1295 for muscle gain or fat loss as an outcome. The existing study measured GH and IGF-1 blood levels, not body composition. Claims about muscle or fat effects are extrapolated from general GH physiology or come from anecdotal community reports, not controlled trial data.
Who developed CJC-1295 and the DAC technology?
ConjuChem Biosciences developed the Drug Affinity Complex (DAC) technology, which chemically links a peptide to albumin in the bloodstream to extend its half-life. CJC-1295 was one of their lead applications of this platform, and the 2005 human study was conducted in connection with that development program.
Is there a comparison study between DAC and no-DAC CJC-1295?
No. No published trial has directly compared CJC-1295 with DAC against the no-DAC (Mod GRF 1-29) version on any human outcome. The theoretical case for no-DAC producing more pulsatile, natural-feeling GH release is grounded in known GH physiology, but it's a hypothesis, not a tested head-to-head result.
Is CJC-1295 legal to buy and use?
It falls in a gray area: not FDA-approved for human use, often sold labeled 'research use only,' but used off-label by some clinics and individuals. It isn't a scheduled controlled substance federally, but that's different from being an approved or clearly legal-for-human-use product. Check current state-level rules and provider documentation before buying.
What dose was used in the CJC-1295 human study?
The Teichman 2005 trial used weight-based microgram-per-kilogram dosing across single and multiple-dose cohorts, spaced roughly one to two weeks apart for repeat dosing, reflecting the DAC version's extended half-life. This differs substantially from typical community daily-dosing protocols for the no-DAC version, which aren't based on a dedicated trial of that form.
Sources
- National Center for Biotechnology Information (NCBI Bookshelf), GHRH and DPP-4 background: GHRH is normally degraded rapidly by DPP-4, and CJC-1295 is modified to resist this degradation
- Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism, 2005: Single and repeated CJC-1295 dosing produced sustained increases in GH and IGF-1, reported as safe and well tolerated in the studied cohorts
- Endotext (NCBI Bookshelf), Physiology of Growth Hormone Secretion: GHRH triggers pulsatile GH release from the anterior pituitary, established through decades of animal and human physiology research
- US Patent and Trademark Office, ConjuChem DAC-modified peptide patent family: Drug Affinity Complex (DAC) technology was developed by ConjuChem to extend peptide half-life via albumin binding
- FDA, Egrifta (tesamorelin) label and approval history: Tesamorelin is FDA-approved for HIV-associated lipodystrophy based on Phase 3 clinical trial data
- FDA, guidance on bulk drug substances for compounding: CJC-1295 is not an FDA-approved drug substance and has raised concerns as a compounded bulk substance lacking adequate safety/efficacy data
- NCBI Bookshelf, Endotext, Growth Hormone Releasing Peptides: Ipamorelin acts through the ghrelin receptor, a distinct pathway from GHRH receptor agonists like CJC-1295
- PubMed, early ipamorelin human pharmacology studies: Ipamorelin underwent early-phase human studies assessing GH release, with development later discontinued for its original indications
- FDA, Geref (sermorelin) historical drug approval record: Sermorelin (Geref) previously held FDA approval before being discontinued from the market